Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
1.725
-0.095 (-5.22%)
Mar 31, 2025, 1:23 PM EDT - Market open
Nuvation Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 8.33, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 382.90% from the current stock price of 1.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +479.71% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $10 | Strong Buy | Maintains | $11 → $10 | +479.71% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $11 | Strong Buy | Maintains | $10 → $11 | +537.68% | Jan 23, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $6 → $10 | Buy | Reiterates | $6 → $10 | +479.71% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +305.80% | Jan 6, 2025 |
Financial Forecast
Revenue This Year
11.65M
from 7.87M
Increased by 47.99%
Revenue Next Year
75.94M
from 11.65M
Increased by 551.81%
EPS This Year
-0.67
from -2.11
EPS Next Year
-0.68
from -0.67
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.6M | 128.4M | 254.6M | ||
| Avg | 11.7M | 75.9M | 157.5M | ||
| Low | 5.4M | 24.5M | 65.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 187.2% | 1,001.7% | 235.3% | ||
| Avg | 48.0% | 551.8% | 107.4% | ||
| Low | -31.5% | 110.3% | -14.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | -0.54 | -0.43 | ||
| Avg | -0.67 | -0.68 | -0.57 | ||
| Low | -0.72 | -0.87 | -0.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.